[{"orgOrder":0,"company":"Lo.Li. Pharma International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lo.Li. Pharma International","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lo.Li. Pharma International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lo.Li. Pharma International \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Charles Drew University of Medicine and Science","sponsor":"National Institute on Minority Health and Health Disparities | Watts Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Muscarinic acetylcholine receptor M2 (CHRM2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Charles Drew University of Medicine and Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charles Drew University of Medicine and Science \/ National Institute on Minority Health and Health Disparities | Watts Healthcare Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Charles Drew University of Medicine and Science \/ National Institute on Minority Health and Health Disparities | Watts Healthcare Corporation"},{"orgOrder":0,"company":"Pharmass\u00eatX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Pharmass\u00eatX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmass\u00eatX \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pharmass\u00eatX \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Neurology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"||Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Oncology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Lo.Li.Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Fatty acid synthase (FASN)","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Lo.Li.Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lo.Li.Pharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Lo.Li.Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lo.Li.Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Fatty acid synthase (FASN)","graph1":"Oncology","graph2":"Undisclosed","graph3":"Lo.Li.Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lo.Li.Pharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Lo.Li.Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Lo.Li.Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Fatty acid synthase (FASN)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Lo.Li.Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lo.Li.Pharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Lo.Li.Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Activ'inside","sponsor":"Complife Italia Srl","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Activ'inside","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Activ'inside \/ Complife Italia Srl","highestDevelopmentStatusID":"1","companyTruncated":"Activ'inside \/ Complife Italia Srl"},{"orgOrder":0,"company":"AMOREPACIFIC CORPORATION","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"AMOREPACIFIC CORPORATION","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMOREPACIFIC CORPORATION \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AMOREPACIFIC CORPORATION \/ Inapplicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Solutions \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Therapeutic Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Taipei Medical University","sponsor":"Eagletek Corp.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Muscarinic acetylcholine receptor M2 (CHRM2)","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Taipei Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taipei Medical University \/ Eagletek Corp.","highestDevelopmentStatusID":"1","companyTruncated":"Taipei Medical University \/ Eagletek Corp."},{"orgOrder":0,"company":"Adamas Biotech S.r.l.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Adamas Biotech S.r.l.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adamas Biotech S.r.l. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Adamas Biotech S.r.l. \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for (-)-Epigallocatechin gallate, EGCG

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Adamas Biotech S.r.l.

                          Country arrow
                          World Drug Safety EU
                          Not Confirmed

                          Adamas Biotech S.r.l.

                          Country arrow
                          World Drug Safety EU
                          Not Confirmed

                          Details : Green Tea Extract is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Constipation-associated with Irritable Bowel Syndrome.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          July 30, 2025

                          Lead Product(s) : Green Tea Extract

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Taipei Medical University

                          Country arrow
                          World Drug Safety EU
                          Not Confirmed

                          Taipei Medical University

                          Country arrow
                          World Drug Safety EU
                          Not Confirmed

                          Details : Green Tea is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Hypercholesterolemia.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          May 28, 2025

                          Lead Product(s) : Green Tea Extract

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Eagletek Corp.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          World Drug Safety EU
                          Not Confirmed
                          World Drug Safety EU
                          Not Confirmed

                          Details : PSX-514 (epigallocatechin gallate) is a small molecule, amyloid precursor protein (APP) inhibitor indicated for the treatment of inflammatory bowel disease pouchitis.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          October 07, 2024

                          Lead Product(s) : Green Tea Extract

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Charles Drew University of Medicine and Science

                          Country arrow
                          World Drug Safety EU
                          Not Confirmed

                          Charles Drew University of Medicine and Science

                          Country arrow
                          World Drug Safety EU
                          Not Confirmed

                          Lead Product(s) : Green Tea Extract

                          Therapeutic Area : Oncology

                          Study Phase : Phase I/ Phase II

                          Sponsor : National Institute on Minority Health and Health Disparities | Watts Healthcare Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          September 27, 2024

                          Lead Product(s) : Green Tea Extract

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : National Institute on Minority Health and Health Disparities | Watts Healthcare Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          World Drug Safety EU
                          Not Confirmed
                          World Drug Safety EU
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          September 19, 2024

                          Lead Product(s) : Green Tea Extract

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Activ'inside

                          Country arrow
                          World Drug Safety EU
                          Not Confirmed

                          Activ'inside

                          Country arrow
                          World Drug Safety EU
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          August 09, 2024

                          Lead Product(s) : Green Tea Extract

                          Therapeutic Area : Dermatology

                          Highest Development Status : Undisclosed

                          Sponsor : Complife Italia Srl

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Lo.Li.Pharma

                          Country arrow
                          World Drug Safety EU
                          Not Confirmed

                          Lo.Li.Pharma

                          Country arrow
                          World Drug Safety EU
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          February 29, 2024

                          Lead Product(s) : Green Tea Extract

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          World Drug Safety EU
                          Not Confirmed
                          World Drug Safety EU
                          Not Confirmed

                          Details : Phase III Adult Stem Cell Company Covers Ability of its COVID-19 Nutraceutical to Repair Injured Brain Cells and Stimulate Endogenous Brain Stem Cells comprising administration of green tea and/or an extract.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          November 28, 2022

                          Lead Product(s) : Green Tea Extract,Broccoli Extract,Nigella Sativa Extract

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Lo.Li.Pharma

                          Country arrow
                          World Drug Safety EU
                          Not Confirmed

                          Lo.Li.Pharma

                          Country arrow
                          World Drug Safety EU
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          November 22, 2022

                          Lead Product(s) : Green Tea Extract

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Lo.Li.Pharma

                          Country arrow
                          World Drug Safety EU
                          Not Confirmed

                          Lo.Li.Pharma

                          Country arrow
                          World Drug Safety EU
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          July 07, 2022

                          Lead Product(s) : Green Tea Extract

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank